values that suppose higher efficacy than may be the situation (i.e., the design could treat the top on the curve as staying equivalent towards the nominal comprehensive agonist). At the level of bias Assessment (??log R0 0 Reply The views expressed Here i will discuss the views of the writer and do not always mirror the sights and thoughts of stori